@8thmaker: I am not misrepresenting anything. What in the heck makes you think so? Quite absurd in your conclusion. By saying only a Phase 2b trial, I am pointing out that the FDA granted the RAT/RMAT designation to Vericel's treatment which hadn't even started a Phase 3 trial when in comparison, Mesoblast's CHF and GvHD already have progressed quite a bit on Phase 3.
The Vericel example is not a knock on Vericel.
Apparently you have not read my previous posts on this very same topic and are nit-picking on words (singluar/plural, blah, blah).
My post also affirms what SI has said regarding several of Mesoblast's therapies being candidates for the RAT/RMAT designation (from the JPM Conference in January 2017), despite only 2 of the 6 being in Phase 3. Some here questioned me in the past about FDA granting that designation without even entering a Phase 3.
Don't be accusing me of misrepresenting anything with your perceived and misguided impressions.
MSB Price at posting:
$2.29 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)